AUTHORS
Jinming Song, MD, PhD, Hailing Zhang, MD2, Lynn Moscinski, MD3, Xiaohong Zhao, MD, PhD4, Julie Li, MD5
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
ABSTRACT
Background:
CHEK2 encodes a checkpoint kinase central to the ATM–CHK2–p53 DNA damage response axis. Existing data derive predominantly from germline-ascertained cohorts, while the somatic mutational landscape remains poorly characterized. We therefore performed a single-institution analysis of patients undergoing NGS for suspected myeloid neoplasms using a panel that includes CHEK2. To our knowledge, this study represents one of the largest single-center series.
Methods and Materials:
Out of the Moffitt NextGen sequencing database of approximately 5157 patients, we identified 46 patients with CHEK2 somatic mutations, which excludes germline-range variant allele frequency (VAF) of 45–55% or >90%, except for newly detected variants without prior history regardless of VAF. Overall survival (OS) was defined as the time from sequencing to the last visit at Moffitt or death.
Results:
Of 5,157 patients, 46 (0.89%) harbored a somatic CHEK2 mutation. Sex distribution was even (23 female, 23 male), with a median age of 68.5 years. The median overall survival is 17.08 months (8.9-47.6). Clonal cytopenia of undetermined significance(CCUS) was the most common diagnosis (16/46, 34.8%, including 11 post cytotoxic CCUS-pCT), followed by acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) (n=10, 21.7% each), MDS-MPN overlap (n=5, 10.9%), and single cases of chronic lymphocytic leukemia, multiple myeloma, systemic mastocytosis, hairy cell leukemia, and post-transplant patient (n=5, 13.0%). In this cohort, 15 patients (33%) had a documented history of prior cytotoxic therapy (pCT) for an antecedent malignancy, most commonly plasma cell neoplasm (PCN) (6/15 pCT patients, 40%; 6/11 CCUS-pCT cases, 55%). CCUS was significantly enriched among PCN (83%, 5/6) compared to those without (28%, 11/40; p value 0.015, OR 13.2).
The median CHEK2 VAF across the cohort was 8.25% (range 2.6–66.6%). The majority of patients (34/46, 74%) had a VAF <=15%, a range most consistent with a low-burden acquired clone in the setting of clonal hematopoiesis. Only 9 of 46 patients (20%) had CHEK2 as the sole detectable mutation (VAF >=2%). The most frequently co-mutated genes were DNMT3A (21.7%), ASXL1 (17.4%), JAK2 (15.2%), TET2 (13.0%), RUNX1 (8.7%), and TP53 (8.7%), supporting CHEK2 acting largely as a cooperating or passenger-like lesion, consistent with prior reports that CHEK2 predisposes to and co-occurs with clonal hematopoiesis rather than serving as a primary leukemic driver. Patients with pCT had lower CHEK2 VAF and fewer co-mutated genes. This pattern is consistent with closer post-treatment surveillance catching these DNA-damage-response–selected clones earlier and smaller.
Interestingly, patients with co-mutation of JAK2 showed significantly better overall survival (OS) by Kaplan-Meier analysis (p value 0.0455), while the median OS time is also much longer than patients without JAK2 co-mutations (38.03 vs 14.33 months, p value 0.06386). As expected, patients with a diagnosis of post cytotoxic treatment myeloid neoplasms showed worse median OS time than patients without (11.8 vs 23.07 months, p value 0.04267).
Discussion:
CHEK2 mutations were identified in 0.89% of patients, confirming that somatic CHEK2 alterations, while uncommon, are not negligible in routine clinical sequencing. The predominance of low-VAF clones and the low rate of CHEK2 as a sole mutation support a model in which CHEK2 loss most often arises as a cooperating lesion within a broader clonal hematopoiesis background rather than as a primary disease driver. This is reinforced by the co-mutation landscape, dominated by canonical age-related clonal hematopoietic genes (DNMT3A, ASXL1, TET2) alongside JAK2.
A history of prior cytotoxic therapy was common, particularly among patients with an antecedent plasma cell neoplasm, in whom CCUS was significantly enriched. Notably, pCT-associated clones had lower VAF and fewer co-mutations, likely reflecting earlier detection through intensive post-treatment surveillance.
Among co-mutations, JAK2 was associated with significantly improved OS, suggesting that CHEK2 mutations arising on an MPN background may behave differently — and more favorably — than those arising in the setting of myelodysplastic or therapy-related clonal evolution. Larger, prospective, multi-institutional cohorts are needed to clarify the independent prognostic contribution of CHEK2.
DISCLOSURES
Jinming Song, MD, PhD: No relevant conflicts of interest to declare.